A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Patients who undergo PET-CT scans to look for cancer are given an intravenous contrast (FDG)
that is taken-up by active cells such as cancer cells. This contrast can then be seen in the
body using the PET-CT scanner. However, cells in the colon also take up the FDG, and can
produce "false positive" signals from the colon. Our hypothesis is that much of this signal
comes from bacteria that are present in high concentrations in the colon. If this is the
case, using an antibiotic to suppress the activity of bacteria may improve the ability of
PET-CT to distinguish abnormal cells from normal cells in the colon.
Phase:
N/A
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Bausch Health Americas, Inc. Valeant Pharmaceuticals International, Inc.